Posted on 30/06/2009 in Pharmaceutical Company Product News
Takeda has submitted additional requests for Alogliptin (SYR-322).
On September 29th 2008, a new drug application for the medication as a monotherapy was submitted and it is currently being evaluated by the authorities.
Now, the company has also put forward an indication of the therapy for combination use with thiazolidinediones, as well as a further submission for a fixed dose of it with pioglitazone HCl (Actos).
Discovered by Takeda's wholly owned subsidiary Takeda San Diego, Alogliptin belongs to the DPP-4 inhibitors class.
These are new oral agents for the treatment of type 2 diabetes and work by slowing the inactivation of incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.
It is thought the proposed combinations could have a number of benefits for sufferers of the condition.
The company stated: "Takeda will continue with its efforts to provide new treatment options for type 2 diabetes to both patients and healthcare professionals."
Earlier this week, the firm received a complete response letter about Alogliptin from the Food and Drug Administration.
